Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 wild-type |
Therapy | Cisplatin + SAR405838 |
Indication/Tumor Type | salivary gland adenoid cystic carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | salivary gland adenoid cystic carcinoma | predicted - sensitive | Cisplatin + SAR405838 | Preclinical - Pdx | Actionable | In a preclinical study, the combination of SAR405838 (MI-773) and Platinol (cisplatin) resulted in increased Tp53 and Mdm2 expression, and demonstrated improved efficacy over either agent alone in TP53 wild-type patient-derived xenograft (PDX) models of salivary gland adenoid cystic carcinoma, resulting in tumor regression without tumor rebound after cessation of therapy (PMID: 27550999). | 27550999 |
PubMed Id | Reference Title | Details |
---|---|---|
(27550999) | Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. | Full reference... |